Foundayo

News

Online pharmacies operating in the UK breached Advertising Standards Authority rules by promoting oral weight drugs to the public.

News

Eli Lilly's bid to dominate the next generation of weight-loss therapies has been strengthened by data on its new combination therapy EloraTZP.

News

Eli Lilly has revealed more data with its triple G agonist retatrutide, boosting its credentials as the next big thing in cardiometabolic diseases.

News

Eli Lilly has announced that orforglipron (Foundayo) is now available to be prescribed for eligible adults via private prescription.

News

Eli Lilly's oral GLP-1 agonist Foundayo has been approved for weight management and type 2 diabetes in the UK, its first European market.

News

Eli Lilly has posted another record quarter of revenue growth, up 48% to $23bn, with Mounjaro and Zepbound now making up two-thirds of the total.